Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study.

Farge D, Loisel S, Resche-Rigon M, Lansiaux P, Colmegna I, Langlais D, Charles C, Pugnet G, Maria ATJ, Chatelus E, Martin T, Hachulla E, Kheav VD, Lambert NC, Wang H, Michonneau D, Martinaud C, Sensebé L, Cras A, Tarte K.

Open source

DOI: 10.1016/s2665-9913(21)00326-x
Published: 2022-01-05
Container: Lancet Rheumatol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2665-9913-21-00326-x,
  title = {Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study.},
  author = {Farge D and  Loisel S and  Resche-Rigon M and  Lansiaux P and  Colmegna I and  Langlais D and  Charles C and  Pugnet G and  Maria ATJ and  Chatelus E and  Martin T and  Hachulla E and  Kheav VD and  Lambert NC and  Wang H and  Michonneau D and  Martinaud C and  Sensebé L and  Cras A and  Tarte K.},
  year = {2022},
  journal = {Lancet Rheumatol},
  doi = {10.1016/s2665-9913(21)00326-x},
  url = {https://doi.org/10.1016/s2665-9913(21)00326-x}
}

RIS

TY  - JOUR
TI  - Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study.
AU  - Farge D
AU  -  Loisel S
AU  -  Resche-Rigon M
AU  -  Lansiaux P
AU  -  Colmegna I
AU  -  Langlais D
AU  -  Charles C
AU  -  Pugnet G
AU  -  Maria ATJ
AU  -  Chatelus E
AU  -  Martin T
AU  -  Hachulla E
AU  -  Kheav VD
AU  -  Lambert NC
AU  -  Wang H
AU  -  Michonneau D
AU  -  Martinaud C
AU  -  Sensebé L
AU  -  Cras A
AU  -  Tarte K.
PY  - 2022
JO  - Lancet Rheumatol
DO  - 10.1016/s2665-9913(21)00326-x
UR  - https://doi.org/10.1016/s2665-9913(21)00326-x
ER  -

APA

D, F., S, L., M, R., P, L., I, C., D, L., C, C., G, P., ATJ, M., E, C., T, M., E, H., VD, K., NC, L., H, W., D, M., C, M., L, S., A, C., & K., T. (2022). Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study.. Lancet Rheumatol. https://doi.org/10.1016/s2665-9913(21)00326-x

Source records

europe-pmc · retrieved 2026-09-26T03:12:15.214Z
hal · retrieved 2026-09-26T03:12:15.227Z